Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin - Wikidata - awgldk - TriplyDB

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

http://www.wikidata.org/entity/Q33890846

about

Cutaneous angiosarcoma: update on biology and latest treatment.Lipid Nanoparticles Decorated with TNF-Related Aptosis-Inducing Ligand (TRAIL) Are More Cytotoxic than Soluble Recombinant TRAIL in Sarcoma.Patients with osteosarcoma and soft tissue sarcoma might become "cancer refugees" in some Japanese regional cities.

P2860

Q47807442-25B19FCE-6182-4A46-BFB9-F45CF37BC2E3 Q53682889-7047E583-7738-4EEA-8125-63260C26688B Q55024248-EE3EE9E3-4746-4A3A-8846-C8EDE4FD5DC7

P2860

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

http://www.wikidata.org/entity/Q33890846

description

2017 nî lūn-bûn

@nan

2017 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Systemic Therapy for Soft Tiss ...... nib, Trabectedin, and Eribulin

@ast

Systemic Therapy for Soft Tiss ...... nib, Trabectedin, and Eribulin

@en

type

label

Systemic Therapy for Soft Tiss ...... nib, Trabectedin, and Eribulin

@ast

Systemic Therapy for Soft Tiss ...... nib, Trabectedin, and Eribulin

@en

prefLabel

Systemic Therapy for Soft Tiss ...... nib, Trabectedin, and Eribulin

@ast

Systemic Therapy for Soft Tiss ...... nib, Trabectedin, and Eribulin

@en

P1433

Q33890846-33164AD1-102F-4CE0-A5AD-2C0774AD2BCC

P1476

Q33890846-787AA29D-BA37-41FB-8977-58119E4C6607

P2093

Q33890846-1CEABAA2-0756-4759-A94B-9B5B670F8307

Q33890846-B93936F0-5344-45B4-9FEE-B05EFF0ACCA7

Q33890846-C52E78B0-71C7-45FD-BD54-41C280987BD8

Q33890846-CB2CE511-392F-48A5-A054-494FA59C68F1

Q33890846-D1CC836E-527A-4560-909C-385479F16FFD

P2860

Q33890846-02A8AC98-5D64-4DA9-8685-A7900F09D08A

Q33890846-0CF32780-1479-406A-BBC9-802969BDA660

Q33890846-0E787FB7-AC40-42D9-AC47-A4289132315B

Q33890846-125A8D6B-79A9-4EF4-A451-A073C06539B4

Q33890846-2E4AADE3-1FCE-4C39-AA64-7BD4BE396B52

Q33890846-2E8E9B08-2FA1-441D-9E8F-E7A5869CEDB1

Q33890846-50FB9F1D-AFAB-4C42-908B-38614BB800FC

Q33890846-6E717B92-E28F-4D51-84BC-2A08C6117DF8

Q33890846-717EAFD8-4E03-4A3D-9F31-43A644B46A60

Q33890846-728EC3D2-E53D-4779-AE03-BBC148C75F98

P2888

Q33890846-8DB0C908-0388-41F9-AFFF-7F1CAB19FAAB

P304

Q33890846-A8A2DAFD-EA6C-4120-B6A8-76F960BDD577

P31

Q33890846-50326899-4951-43B7-B6E5-E822021C90C1

Q33890846-7167CB16-6BC5-4586-AEA3-966855CC4368

P356

Q33890846-D766068A-771F-4F1C-A3DF-D6C01A98B375

P407

Q33890846-B3720544-42C8-4C6F-9B94-783A0E489369

P433

Q33890846-8E48A4EB-814B-4C08-A0B1-098B015D0464

P478

Q33890846-6EB243C1-9724-4A7F-A26F-A58131CCB6B8

P577

Q33890846-026EBD20-2BEF-4ACD-8567-DF71B5643677

Q33890846-091D9D06-5006-4B2F-8065-33A8EA0F6245

P6179

Q33890846-DEAB8382-2734-434F-89FB-CD69B1ECD567

P698

Q33890846-F7D937CD-0093-48BE-BB4B-1189F3018603

P921

Q33890846-41B7372F-8B59-4C37-907C-83A2759EC121

Q33890846-4C9743A1-E104-45B8-AD50-27C4F32496E4

Q33890846-724595C7-0F72-40EA-B034-21AA17D11422

Q33890846-79215093-AE8D-4656-974F-117EFDCA0FDF

Q33890846-AF5440BF-8FC4-4DB3-BCF9-B8F299C04057

Q33890846-D0D0F136-D8F5-4B38-A075-A18244D608A3

P932

Q33890846-009AABC4-A592-4B1F-8B36-23F75D762AF5

P356

S12325-017-0561-4

P1433

Advances in Therapy

P1476

Systemic Therapy for Soft Tiss ...... nib, Trabectedin, and Eribulin

@en

P2093

Akira Kawai

http://www.w3.org/2001/XMLSchema#string

Kan Yonemori

http://www.w3.org/2001/XMLSchema#string

Nobuhito Araki

http://www.w3.org/2001/XMLSchema#string

Shunji Takahashi

http://www.w3.org/2001/XMLSchema#string

Takafumi Ueda

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the management of soft tissue sarcomas

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

P2888

s12325-017-0561-4

P304

1556-1571

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-017-0561-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085593448

http://www.w3.org/2001/XMLSchema#string

P698

28547734

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

mechanism of action

epithelioid sarcoma

P932

5504216

http://www.w3.org/2001/XMLSchema#string